Abstract

1
Background and aims: Hepatitis C virus (HCV) incidence among HIV-positive men 2 who have sex with men (MSM) has increased since 2000, though regional 3 differences have been documented in recent years. We aimed to 1) estimate trends 4 in HCV incidence among HIV-positive MSM, 2) assess the association between 5 incidence and geographical region, age and HIV-related measurements and, 3) 6 assess temporal changes in time from HIV seroconversion to HCV infection. 
Methods:
We used data from MSM with well-estimated dates of HIV seroconversion 9 from the CASCADE Collaboration (1990 Collaboration ( -2014 . We allowed for smoothly varying 10 trends in HCV incidence over calendar time using restricted cubic splines. We levels were significantly associated with HCV incidence, while CD4 count was not.
19
Trends differed by geographical region; while incidence appears to have stabilized in 20 Western Europe and remained stable in Southern Europe, it continued to increase in 
8
A recent meta-analysis showed that HCV incidence has continued to increase, with 9 an estimated pooled incidence of 13/1000 person-years (py) in 2010 to an 10 extrapolated incidence estimate of 19/1000 py in 2015 [2] . However, other studies 11 have shown varying trends in HCV incidence among MSM over the past years [3, 4] .
12
In Amsterdam, the Netherlands, HCV incidence seems to be stabilizing [3] , whereas 13 in Switzerland an increasing incidence among MSM has been observed [4] . T-cell count (CD4 count) and HCV incidence have been reported [4, 9, 10, 12] .
24
Additionally, few studies have investigated the association with HIV RNA and, those Using data among MSM with well-estimated dates of HIV seroconversion from the 5 CASCADE Collaboration we aimed to 1) update trends in HCV incidence; overall 6 and by geographical region, 2) assess the associations between HCV incidence and 7 HIV-related measurements, geographical region, age and calendar year, and 3) 8 assess whether the time interval between HIV seroconversion and HCV infection has 9 changed over calendar time.
10
Methods
1
We used data from 16 out of 28 cohorts from the CASCADE Collaboration across 2 Europe, Australia and Canada. Of the excluded cohorts, 5 were non-MSM cohorts 3 and 6 cohorts had tested less than 50% of MSM for HCV and could not provide 4 stored samples for HCV testing (missing HCV status data from 57.2% to 96.2%) 5 (Fig. 1) 
HCV risk factor analyses
21
We used three Poisson regression models that included calendar year using the 22 method 1 approach to calculate follow-up. We assessed variation of HCV incidence 
Model 2 8
We then added age to the best fitting model 1. In this model, we tested the 9 interaction between age and both region and calendar year. Significant interactions 10 were included in this model. performed where the antepenultimate CD4 count and HIV RNA value were used.
13
The reason for the third analysis is that antibody development might be delayed in 
Results
1
Of 17,429 HIV-positive MSM, 7,368 MSM were excluded from 6 cohorts with more 2 than 50% missing HCV status data and that could not provide stored samples for 3 HCV testing (Fig. 1) in 2014 in method 2 (Fig. 2) . The interval-censored method showed a similar 6 increasing trend ( Supplementary Fig. 1 ). Excluding one cohort (ICoNA) from the 7 overall analyses, led to similar statistically significant increasing trends by both 8 methods, although the estimations were slightly lower ( Supplementary Fig. 2 ). The 9 stratified analyses by geographical region showed that in recent years HCV 10 incidence seems to have increased in Northern Europe, but calendar year was only 11 statistically significant in method 2 (p=0.02) (Fig. 3) The first analysis showed that the model with region and calendar year as main 20 effects only (model 1.2) had the lowest AIC of the three submodels, thus the best fit.
21
The second model showed that younger HIV-positive MSM had a higher risk of HCV 22 infection (p=0.005) (Fig. 4A ). The interaction term between age and region was borderline significant (p=0.05). Based on the model with the interaction term, in 1 Western Europe, HCV incidence remained highest and stable until around age 35 2 and declined thereafter ( Supplementary Fig. 3 ). In Northern and Southern Europe,
3
HCV incidence increased until age 35, and declined thereafter.
4
In the third model, a higher HIV RNA was associated with higher HCV incidence 5 (p=0.001) (Fig. 4C) , especially when log 10 HIV RNA was ≥5 copies/mL, whereas 6 CD4 count (Fig. 4B) 
Sensitivity analyses
15
All sensitivity analyses showed comparable associations of HIV RNA, CD4 count 16 and calendar year with HCV incidence and the conclusions were not altered.
17
However, in the complete case analyses, HIV RNA was non-significant (p=0.25)
18
( Supplementary Fig. 4) .
19
In the model that included HIV infection stage, two sensitivity analyses (i.e.,
20
antepenultimate and predicted values) showed comparable associations between
21
HIV RNA and HCV incidence, but when antepenultimate HIV RNA values were used, the association was no longer statistically significant (p=0.09). In the complete case 1 analyses, there was no association (p=0.40). higher HIV RNA levels might be surrogate for poor adherence to cART.
7
Unfortunately, we could not assess the effect of STIs and cART adherence on HCV 8 incidence, as most cohorts do not collect these data.
10
We found no association between HCV incidence and CD4 count, which is in line 11 with most studies [3, 4, 6, 12] such as IDU, in the majority of MSM [4, 5, [7] [8] [9] [10] 12] . Hence, the increase in sexual risk . In addition, due to a lack of country specific HCV testing 7 guidelines (e.g., Italy), HCV testing practices may not be systematic.
9
The strengths of our study are that we had data from HIV seroconversion onwards
10
for a large group of MSM, and extensive follow-up that enabled us to assess as HCV testing was only systematically recorded until that year.
7
The grey boxes depict MSM whose data were excluded from the analyses. The relative hazards obtained from the regression models were translated into the 12 predicted incidence and this is illustrated for certain values of the covariates (e.g.,
13
only for Western Europe). Curves were truncated when less than 10 individuals were at risk for HCV infection.
20
The log-rank test was used to assess changes in the time from HIV seroconversion 21 to HCV infection among calendar periods. log HIV RNA (lagged) (copies/mL) HCV incidence rate per 1000 py log HIV RNA (lagged) (copies/mL) HCV incidence rate per 1000 py (D)
